Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor ALPK1 Inhibitor, DF-003

2023-09-19

临床1期

First-in-human trial for DF-003, the 2nd compound from IDInVivo and MedChem5 platform to enter clinical trials GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)-- Drug Farm, a clinical-stage biopharmaceutical company, announced today that the first subject in the Phase 1 clinical trial (NCT05997641) evaluating DF-003 in healthy volunteers has been dosed. DF-003, discovered through Drug Farms’ IDInVivo and MedChem5 platform technologies, is an investigational small molecule drug that inhibits alpha-kinase 1 (ALPK1), a key target regulating inflammation pathways that underly disease pathology in cardio-renal diseases. A gain-of-function mutation in ALPK1 also causes a rare genetic disease, ROSAH syndrome, that leads to blindness. “We are excited to see the fruits of our technology lead to the initiation of this study for the first-in-class drug, DF-003,” said Dr. Tony Xu, Ph.D., co-founder and Chief Operating Officer of Drug Farm. DF-003 is a potent, highly selective, orally bioavailable ALPK1 inhibitor ALPK1 inhibitor with preclinical efficacy in cardio-renal and ROSAH disease animal models. “The Phase 1 study will evaluate DF-003 in healthy volunteers with single and multiple ascending doses that will inform dose selection for the Phase 2 programs. We look forward to completing the Phase 1 study and providing a new therapeutic option for patients afflicted with heart and kidney disease, and ROSAH syndrome,” said Drug Farm’s Chief Medical Officer, Dr. Jeysen Yogaratnam, MB.BCh, MRCSEd, Ph.D., MBA. About Drug Farm Drug Farm is a private biotechnology Company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: View source version on businesswire.com: Contacts United States: Henri Lichenstein, Ph.D. Chief Executive Officer hlichens@drug-farm.com China: Tony Xu, Ph.D. Co-founder and Chief Operating Officer tony.xu@drugfarminc.com Source: Drug Farm View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构